DOWNSTREAM PROCESSING FEATURED ARTICLES
Genetic Immunity (OTCBB: PWRV), a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx.
-
![All Hands In]( "COVID-19 Consortium: Competitive Collab On A Plasma-Derived Therapy")
COVID-19 Consortium: Competitive Collab On A Plasma-Derived TherapyA host of global biopharma competitors are collaborating under the CoVIg-19 Plasma Alliance to secure enough convalescent plasma to produce an effective COVID-19 therapeutic at global scale. Takeda’s Dr. Thomas R. Kreil will present at the upcoming FDA/Xavier PharmaLink Conference.
-
Ablynx And Its Partner Advance Nanobody Candidate ALX-0751 In Pre-Clinical Development
Ablynx [Euronext Brussels: ABLX] today announced that they have advanced the Nanobody(®) candidate ALX-0751, together with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, into pre-clinical development in the field of oncology.
-
![Fluid]( "One-Touch Single-Use Fluid Path Assemblies Enhance Operational Flexibility")
One-Touch Single-Use Fluid Path Assemblies Enhance Operational Flexibility Meissner’s One-Touch single-use fluid path assemblies are designed for secure fluid transfer in critical biopharmaceutical processing applications. The assemblies reduce process risk while providing an enhanced level of convenience that maximizes flexibility in the deployment of singleuse systems, as well as conventional systems.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Important Considerations For Implementing A Single-Use Biomanufacturing Strategy
Recent trends in biomanufacturing technology and the biopharmaceutical market are supporting the increased adoption of single-use (SU) manufacturing systems. On the demand-side, the biopharma industry is focusing on niche and rare diseases with smaller patient populations, resulting in the need for smaller, more agile biomanufacturing capacity. By Jodi M. Zobrist and Nicole W. O'Brien, Ph. D., Gallus Biopharmaceuticals, LLC
-
Biomanufacturing Supply Chains
This white paper examines the major issues with biopharmaceutical supply chains and how to balance inventory and risk optimally in the network.
-
![A Purification Strategy For Clinical-Grade Monoclonal Antibody]( "A Purification Strategy For Clinical-Grade Monoclonal Antibody")
A Purification Strategy For Clinical-Grade Monoclonal AntibodymAbs are currently the most important class of therapeutic proteins. Advances in upstream process technologies have led to tremendous improvement of mAb titers in mammalian cell culture.
-
Optimized Sterile Filtration of Pharmaceutical Solutions
The cost of filtration and separation stages within the production of pharmaceuticals has been increasing along with the increased complexity of final drug products.
-
Metal Removal From Fine Chemical Products
Metal contamination in various injectable or even oral medicines is a serious concern.
-
Biomanufacturing Flexibility
This white paper from BIO-G looks at how to create flexible, agile manufacturing facilities to respond to the current glut of biomanufacturing capacity and industry consolidation. Future proofing these facilities for higher titers and multiple product lines is also explored.
DOWNSTREAM PROCESSING PRODUCTS
Our integrated single-use bioreactors are designed as complete out-of-the-box jacketed systems, each paired with an integrated controller and temperature control unit (TCU).
DOWNSTREAM PROCESSING MULTIMEDIA
Bioprocess With The Bozenhardts is back, with a fresh episode packed with advice from Herman and Erich on the selection of filling systems for biopharmas. Listen in as the Bozenhardts give us an update on the process, logistics, and administration trends that are informing filling system decisions today, and offer direction on making choices that will prepare you for the fast-advancing therapies of tomorrow.
Bio-Rad now offers two very high capacity ion exchangers: Nuvia S, which can be used for capture and/or intermediate polishing; and Nuvia Q, which can be used for intermediate and/or final polishing.